Effect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver Cirrhosis
NCT ID: NCT00332904
Last Updated: 2010-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
22 participants
INTERVENTIONAL
2006-08-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal
NCT01059396
Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation
NCT00839358
Evaluation of Gastrointestinal Transit Pre and Pos Treatment With Non Selective Betablocker in a Population of Cirrhotics
NCT02923336
Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome
NCT00742339
Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites
NCT02163512
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients with liver cirrhosis and portal hypertension are betablockers and/or aldosterone antagonists routine treatment - effects on peripheral hemodynamics and oxygenation in relation to central hemodynamic changes are deficient.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
beta
patients with liver cirrhosis, treated with betablocker
propranolol
tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment
spiron
patients with liver cirrhosis, treated with aldosterone antagonist
spironolactone
tablet 200 mg pr. day in 3 weeks, evt. dose adjustment
control
patients with liver cirrhosis, no treatment
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
propranolol
tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment
spironolactone
tablet 200 mg pr. day in 3 weeks, evt. dose adjustment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical indication for treatment with betablocker or aldosterone antagonist
* Must not have been treated earlier with betablocker or aldosterone antagonist
* Must have been alcohol abstinent for more than 4 weeks
Exclusion Criteria
* Encephalopathy \> grade 1
* Acute medical conditions
* Malignant disease
* Pregnancy
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hvidovre University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hvidovre Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Soeren Moeller, MD, DMSc
Role: STUDY_DIRECTOR
Hvidovre University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Clinical Physiology and Nuclear Medicine, and Department for Gastrointestinal Medicine, Hvidovre Hospital
Hvidovre, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CD-0606-HH-UH-DK
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.